1h Free Analyst Time
The advent of bupivacaine liposome injection has marked a paradigm shift in postoperative pain management by offering extended analgesia and reducing opioid dependence. Unlike conventional formulations, encapsulating bupivacaine in multivesicular liposomes permits sustained drug release over 72 hours, which aligns with the critical window of acute postoperative discomfort. This innovation addresses both clinical and economic imperatives: hospitals and surgical centers benefit from shorter recovery times, lower readmission rates, and enhanced patient satisfaction, while payers and policymakers support value-based care protocols that prioritize safety and cost containment.Speak directly to the analyst to clarify any post sales queries you may have.
Over the past decade, accelerated approvals and real-world evidence have validated the efficacy and safety profile of this long-acting local anesthetic across diverse surgical specialties. As healthcare delivery evolves toward outpatient procedures and same-day discharges, anesthesia strategies that minimize monitoring requirements and opioid-related side effects have become essential. Moreover, rising awareness of the opioid epidemic has catalyzed interest in non-opioid analgesics that can be integrated seamlessly into multimodal pain management pathways.
In this ecosystem, bupivacaine liposome injection is positioned as a cornerstone therapy, addressing acute, chronic, and post-operative pain while supporting enhanced recovery protocols. This executive summary outlines transformative market shifts, regulatory influences, segmentation insights, regional dynamics, and competitive positioning. It serves as a comprehensive guide for decision-makers seeking to optimize adoption, manage cost pressures, and unlock new growth opportunities in the expanding landscape of long-acting local anesthetics.
Transformative Shifts Redefining the Bupivacaine Liposome Market
The bupivacaine liposome market is undergoing transformative shifts driven by regulatory, technological, and care-delivery innovations. Recent approvals in additional surgical indications have broadened the scope beyond orthopedic and cosmetic procedures to encompass cardiovascular and general surgeries. This expansion reflects robust clinical data demonstrating consistent analgesic benefits and reduced opioid consumption across multiple operative settings.Technological advances in liposomal manufacturing have further enhanced product stability and scalability, enabling contract manufacturing organizations to ramp up production and reduce unit costs. As a result, hospitals and surgical centers are more inclined to integrate these formulations into standard protocols. Concurrently, the rise of digital health platforms is facilitating remote monitoring of pain outcomes, creating real-time feedback loops that inform formulary decisions and drive iterative improvements in multimodal analgesia pathways.
Value-based care initiatives and bundled payment models are reshaping procurement strategies, as providers seek to align perioperative pain management with performance metrics such as reduced length of stay and lower readmission rates. With stakeholders demanding quantifiable outcomes, the ability of bupivacaine liposome injection to deliver sustained analgesia without intensive monitoring positions it as a strategic asset for healthcare systems targeting both clinical excellence and financial optimization.
Cumulative Impact of 2025 United States Tariffs on Bupivacaine Liposome
The implementation of new United States tariffs in 2025 on imported raw materials and specialized excipients has introduced significant cost pressures that reverberate across the bupivacaine liposome supply chain. Manufacturers reliant on overseas procurement for phospholipids and cholesterol face increased input costs, which in turn impact pricing strategies for both established and emerging products.In response, several key players have accelerated investments in domestic production capabilities and backward integration initiatives to mitigate tariff exposure and secure uninterrupted supply. This strategic pivot not only stabilizes manufacturing costs but also aligns with federal incentives aimed at bolstering domestic pharmaceutical infrastructure. As a result, contract manufacturers and originators are considering co-location strategies that reduce freight expenses and expedite turnaround times, particularly for time-sensitive surgical procedures.
From a market access perspective, payers and hospital procurement teams are reevaluating formulary placements in light of evolving price dynamics. While short-term cost increases may prompt negotiations on volume rebates and tender contracts, the long-term outlook favors manufacturers that demonstrate supply resilience and cost efficiency. Ultimately, tariff-driven adjustments are catalyzing a reassessment of sourcing strategies, distribution partnerships, and pricing models across the entire value chain.
Key Segmentation Insights Driving Market Dynamics
Disaggregating the bupivacaine liposome landscape through multiple segmentation lenses reveals nuanced drivers of adoption and revenue diversification. When examining the market by application, distinct growth trajectories emerge between acute pain management, chronic pain relief, and post-operative pain control on one hand, and cardiovascular, cosmetic, general, and orthopedic surgeries on the other. Within end users, hospital-affiliated and independent ambulatory surgical centers, specialized pain management and rehabilitation clinics, post-surgery homecare recovery programs, and both general and specialty hospitals exhibit varying adoption rates based on procedural volumes, patient acuity, and reimbursement frameworks.Formulation preferences divide between multi-dose vials, favored by high-volume surgical centers, and single-dose vials, which are preferred for point-of-care administration in outpatient or home settings. Patient demographic analysis underscores the critical role of middle-aged adults, seniors, young adults, and elderly at-risk populations, while adolescents, children, and infants demand tailored dosing and administration protocols. The route of administration spans intramuscular, intravenous, and subcutaneous injections, each offering distinct pharmacokinetic profiles to meet clinical objectives.
Duration of action serves as a key differentiator, with long-acting formulations commanding premium positioning in enhanced recovery pathways, and medium- or short-duration options addressing specific procedural requirements. Variations in drug interaction potential-namely high, medium, or low-necessitate pharmacist and physician collaboration to optimize safety. Finally, distribution through direct tenders, drug stores, and retail pharmacies shapes access, with each channel presenting unique dynamics in pricing, volume contracts, and patient reach.
Key Regional Insights Shaping Adoption and Access
Regional dynamics exert a profound influence on the adoption and diffusion of bupivacaine liposome injection. In the Americas, robust infrastructure for outpatient surgeries and a high prevalence of joint replacement and cosmetic procedures have positioned the region as an early adopter, supported by streamlined regulatory pathways and value-based reimbursement models. Conversely, Europe, Middle East & Africa comprise a fragmented market where reimbursement varies across national healthcare systems, creating pockets of high penetration in Western Europe and the Gulf Cooperation Council, contrasted with slower uptake in emerging African economies due to budgetary constraints.Asia-Pacific is characterized by rapid growth driven by expanding surgical capacity in China, India, and Southeast Asia. Government initiatives aimed at improving access to advanced analgesic therapies, coupled with rising healthcare expenditures, are underpinning significant investments in hospital infrastructure. However, local manufacturing capabilities and import regulations introduce variability in pricing and availability, prompting multinational companies to forge strategic alliances with regional partners. Collectively, these regional insights highlight the importance of tailored market entry strategies that account for regulatory complexity, reimbursement heterogeneity, and evolving healthcare delivery models.
Profile of Key Companies Driving Innovation and Competition
The competitive terrain of bupivacaine liposome injection features a diverse ensemble of global pharmaceutical and contract manufacturing leaders. Amphastar Pharmaceuticals, Inc. leverages its specialty injectable portfolio to expand hospital affiliations, while Aurobindo Pharma USA, Inc. focuses on scale-driven cost efficiencies. B. Braun Melsungen AG and Baxter International Inc. emphasize integrated supply chain capabilities and service-level agreements that secure high-value tenders. Dr. Reddy’s Laboratories and Fresenius Kabi USA, LLC advance regional manufacturing hubs to navigate tariff and regulatory complexities.Legacy players such as Hospira, Inc. (a Pfizer subsidiary) and Mylan N.V. (a Viatris company) continue to refine branded generics strategies, whereas Novartis AG and Sandoz (its division) leverage global reach to optimize pricing across developed and emerging markets. Pacira BioSciences, Inc. remains the market pioneer with differentiated liposomal technology and robust clinical data, while Piramal Pharma Solutions offers contract research and manufacturing services that accelerate time-to-market. Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceuticals complete the landscape with expansive distribution networks and ongoing portfolio expansions through in-licensing and acquisitions.
Actionable Recommendations for Industry Leaders
Industry leaders can capitalize on emerging opportunities by adopting a multifaceted strategic agenda. First, investing in domestic manufacturing or regional supply hubs will mitigate tariff exposure and enhance supply chain resilience, ensuring consistent availability for critical surgical procedures. Second, cultivating collaborative partnerships with hospitals, ambulatory centers, and homecare networks will facilitate protocol integration and real-world evidence generation, reinforcing the value proposition to payers.Third, diversifying the portfolio across multi-dose and single-dose formulations, as well as tailored durations of action, will address the full spectrum of patient and procedural needs. Fourth, leveraging digital health solutions to capture patient-reported outcomes and optimize dosing regimens will differentiate offerings and support premium positioning. Fifth, engaging in value-based contracting and outcome-linked agreements can align stakeholder incentives, streamline reimbursement, and foster long-term adoption.
Finally, robust pharmacovigilance and education initiatives targeting high-interaction potential scenarios will bolster clinician confidence and expand use in complex cases. By executing this holistic playbook, companies can secure market share, drive profitability, and deliver superior patient outcomes in an increasingly competitive environment.
Conclusion: Navigating the Evolving Bupivacaine Liposome Market
The bupivacaine liposome injection market stands at the intersection of clinical innovation, regulatory evolution, and value-based care transformation. Prolonged analgesia has shifted perioperative pain management paradigms, enabling enhanced recovery protocols that reduce hospital stays and minimize opioid exposure. At the same time, tariff adjustments and global supply chain realignments are prompting strategic investments in localized manufacturing and distribution.Segmentation insights reveal differentiated growth engines across pain management and surgical applications, end-user settings, formulation types, patient demographics, administration routes, action durations, interaction profiles, and pharmaceutical channels. Regional dynamics emphasize the Americas’ early adoption, Europe, Middle East & Africa’s regulatory complexity, and Asia-Pacific’s rapid capacity expansion. Competitive analysis underscores the role of both pioneers and contract manufacturers in driving innovation and accessibility.
Moving forward, success will hinge on integrated strategies that combine supply chain agility, clinical partnerships, portfolio diversification, digital evidence generation, and value-based contracting. As stakeholders prioritize outcomes over volume, manufacturers that demonstrate tangible clinical benefits and cost efficiencies will emerge as preferred partners in modern perioperative care.
Market Segmentation & Coverage
This research report categorizes the Bupivacaine Liposome Injection Market to forecast the revenues and analyze trends in each of the following sub-segmentations:
- Pain Management
- Acute Pain
- Chronic Pain
- Post-Operative Pain
- Surgical Procedures
- Cardiovascular Surgeries
- Cosmetic Surgeries
- General Surgeries
- Orthopedic Surgeries
- Ambulatory Surgical Centers
- Hospital-Affiliated Centers
- Independent Centers
- Clinics
- Pain Management Clinics
- Rehabilitation Clinics
- Homecare Settings
- Post-Surgery Recovery At Home
- Hospitals
- General Hospitals
- Specialty Hospitals
- Multi-Dose Vial
- Single-Dose Vial
- Adults
- Middle-Aged Adults
- Seniors
- Young Adults
- Geriatrics
- Elderly At Risk
- Pediatrics
- Adolescents
- Children
- Infants
- Intramuscular
- Intravenous
- Subcutaneous
- Long Duration
- Medium Duration
- Short Duration
- High Interaction Potential
- Low Interaction Potential
- Medium Interaction Potential
- Direct Tenders
- Drug Stores
- Retail Pharmacies
This research report categorizes the Bupivacaine Liposome Injection Market to forecast the revenues and analyze trends in each of the following sub-regions:
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
This research report categorizes the Bupivacaine Liposome Injection Market to delves into recent significant developments and analyze trends in each of the following companies:
- Amphastar Pharmaceuticals, Inc.
- Aurobindo Pharma USA, Inc.
- B. Braun Melsungen AG
- Baxter International Inc.
- Dr. Reddy's Laboratories
- Fresenius Kabi USA, LLC
- Hospira, Inc. (subsidiary of Pfizer)
- Mylan N.V. (a Viatris company)
- Novartis AG
- Pacira BioSciences, Inc.
- Piramal Pharma Solutions
- Sandoz (a Novartis division)
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals
This product will be delivered within 1-3 business days.
Table of Contents
1. Preface1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bupivacaine Liposome Injection Market, by Application
8.1. Introduction
8.2. Pain Management
8.2.1. Acute Pain
8.2.2. Chronic Pain
8.2.3. Post-Operative Pain
8.3. Surgical Procedures
8.3.1. Cardiovascular Surgeries
8.3.2. Cosmetic Surgeries
8.3.3. General Surgeries
8.3.4. Orthopedic Surgeries
9. Bupivacaine Liposome Injection Market, by End Users
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.2.1. Hospital-Affiliated Centers
9.2.2. Independent Centers
9.3. Clinics
9.3.1. Pain Management Clinics
9.3.2. Rehabilitation Clinics
9.4. Homecare Settings
9.4.1. Post-Surgery Recovery At Home
9.5. Hospitals
9.5.1. General Hospitals
9.5.2. Specialty Hospitals
10. Bupivacaine Liposome Injection Market, by Formulation Type
10.1. Introduction
10.2. Multi-Dose Vial
10.3. Single-Dose Vial
11. Bupivacaine Liposome Injection Market, by Patient Demographics
11.1. Introduction
11.2. Adults
11.2.1. Middle-Aged Adults
11.2.2. Seniors
11.2.3. Young Adults
11.3. Geriatrics
11.3.1. Elderly At Risk
11.4. Pediatrics
11.4.1. Adolescents
11.4.2. Children
11.4.3. Infants
12. Bupivacaine Liposome Injection Market, by Route Of Administration
12.1. Introduction
12.2. Intramuscular
12.3. Intravenous
12.4. Subcutaneous
13. Bupivacaine Liposome Injection Market, by Duration Of Action
13.1. Introduction
13.2. Long Duration
13.3. Medium Duration
13.4. Short Duration
14. Bupivacaine Liposome Injection Market, by Drug Interaction Potential
14.1. Introduction
14.2. High Interaction Potential
14.3. Low Interaction Potential
14.4. Medium Interaction Potential
15. Bupivacaine Liposome Injection Market, by Pharmaceutical Channel
15.1. Introduction
15.2. Direct Tenders
15.3. Drug Stores
15.4. Retail Pharmacies
16. Americas Bupivacaine Liposome Injection Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Bupivacaine Liposome Injection Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Bupivacaine Liposome Injection Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Amphastar Pharmaceuticals, Inc.
19.3.2. Aurobindo Pharma USA, Inc.
19.3.3. B. Braun Melsungen AG
19.3.4. Baxter International Inc.
19.3.5. Dr. Reddy's Laboratories
19.3.6. Fresenius Kabi USA, LLC
19.3.7. Hospira, Inc. (subsidiary of Pfizer)
19.3.8. Mylan N.V. (a Viatris company)
19.3.9. Novartis AG
19.3.10. Pacira BioSciences, Inc.
19.3.11. Piramal Pharma Solutions
19.3.12. Sandoz (a Novartis division)
19.3.13. Sanofi
19.3.14. Sun Pharmaceutical Industries Ltd.
19.3.15. Teva Pharmaceuticals
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. BUPIVACAINE LIPOSOME INJECTION MARKET MULTI-CURRENCY
FIGURE 2. BUPIVACAINE LIPOSOME INJECTION MARKET MULTI-LANGUAGE
FIGURE 3. BUPIVACAINE LIPOSOME INJECTION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. BUPIVACAINE LIPOSOME INJECTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. BUPIVACAINE LIPOSOME INJECTION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BUPIVACAINE LIPOSOME INJECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY POST-OPERATIVE PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CARDIOVASCULAR SURGERIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY COSMETIC SURGERIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GENERAL SURGERIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ORTHOPEDIC SURGERIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITAL-AFFILIATED CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY INDEPENDENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY REHABILITATION CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY POST-SURGERY RECOVERY AT HOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY MULTI-DOSE VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SINGLE-DOSE VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY MIDDLE-AGED ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SENIORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ELDERLY AT RISK, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GERIATRICS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY LONG DURATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY MEDIUM DURATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SHORT DURATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HIGH INTERACTION POTENTIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY LOW INTERACTION POTENTIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY MEDIUM INTERACTION POTENTIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DIRECT TENDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GERIATRICS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GERIATRICS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GERIATRICS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 121. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 122. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 123. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 124. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 125. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 126. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 127. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 128. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 129. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 130. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GERIATRICS, 2018-2030 (USD MILLION)
TABLE 131. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 132. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 134. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2018-2030 (USD MILLION)
TABLE 135. CANADA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 138. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 139. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 140. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 142. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 143. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 144. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 145. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 146. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 147. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GERIATRICS, 2018-2030 (USD MILLION)
TABLE 148. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 149. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 151. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2018-2030 (USD MILLION)
TABLE 152. MEXICO BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GERIATRICS, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GERIATRICS, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GERIATRICS, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 208. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 209. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 210. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 211. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 212. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 213. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 214. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 215. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 216. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 217. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GERIATRICS, 2018-2030 (USD MILLION)
TABLE 218. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 219. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 221. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2018-2030 (USD MILLION)
TABLE 222. CHINA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 225. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 226. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 227. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 228. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 229. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 230. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 231. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 232. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 233. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 234. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GERIATRICS, 2018-2030 (USD MILLION)
TABLE 235. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 236. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 238. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2018-2030 (USD MILLION)
TABLE 239. INDIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 251. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GERIATRICS, 2018-2030 (USD MILLION)
TABLE 252. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 253. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2018-2030 (USD MILLION)
TABLE 256. INDONESIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 258. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 259. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 260. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 261. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 262. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 263. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 264. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 265. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 266. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 267. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 268. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GERIATRICS, 2018-2030 (USD MILLION)
TABLE 269. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 270. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 272. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2018-2030 (USD MILLION)
TABLE 273. JAPAN BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 276. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 277. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 278. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 279. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 280. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 281. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 282. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 283. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 284. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 285. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY GERIATRICS, 2018-2030 (USD MILLION)
TABLE 286. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 287. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 289. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY DRUG INTERACTION POTENTIAL, 2018-2030 (USD MILLION)
TABLE 290. MALAYSIA BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PHARMACEUTICAL CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 298. PHILIPPINES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 299. PHILIPPINES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 300. PHILIPPINES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 301. PHILIPPINES BUPIVACAINE LIPOSOME INJECTION MARKET SIZE, BY ADULTS, 2018-2030 (USD M
Companies Mentioned
- Amphastar Pharmaceuticals, Inc.
- Aurobindo Pharma USA, Inc.
- B. Braun Melsungen AG
- Baxter International Inc.
- Dr. Reddy's Laboratories
- Fresenius Kabi USA, LLC
- Hospira, Inc. (subsidiary of Pfizer)
- Mylan N.V. (a Viatris company)
- Novartis AG
- Pacira BioSciences, Inc.
- Piramal Pharma Solutions
- Sandoz (a Novartis division)
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals
Methodology
LOADING...
